# Supersaturation Profile, Urine



Patient:	Client:	ARUP Test Code: 2008771
DOB: Age: Sex:		
Patient Identifiers:		Collection Date: 10/21/2023
	Physician:	Received in lab: 10/22/2023
Visit Number (FIN):		Completion Date: 10/26/2023

Calculus	Calculated Risk	Relative	e Sup	oersa	turat	ion					
		Reduced Risl	k <5							Increas	ed Risk >5
Calcium Oxalate	8.15	0 1 2 3 4	5 6 7	8 9 10	11 12 13	14 15 16	17 18	19 20 21	22 23	24 25 26	27 28 29 30
		Reduced Risl	k <2							Increas	ed Risk >2
Calcium Hydrogen Phosphate	1.20										
		0 1	2 3	3 4	5	6	7	8	9	10	11 12
		Reduced Risl	k <1							Increas	ed Risk >1
Uric Acid	0.70										
		0	1	2		3		4		5	6

Calculated risk is derived by a computer program that models the thermodynamics of calculi formation using measured urine components.

Specimen Condition				
Analyte	Result	Units	Reference Interval	Effect
Hours Collected	24	h	24	Collection for 24 hours reflects daily excretion.
Total Volume	2250	mL	M 800-1800 F 600-1600	Low urine volume (<1L/24h) promotes calculi formation.
рН	5.60		5.00-7.50	Acidic urine (pH<5.5) promotes precipitation of uric acid. A kaline urine (pH>7.2) promotes formation of CaHPO4 stones.
Creatinine	990	mg/d	500-1400	Excretion provides a measure of completeness of 24h urine collection.

#### **Stone Formation Promoters**

Analyte	Result	Units	Reference Interval	Effect
Calcium <sup>1</sup>	448 H	mg/d	100-250	Hypercalciuria (>200 mg/d) promotes formation of CaOx and CaHPO4 stones.
Oxalate	29	mg/d	13-40	Hyperoxaluria (>40 mg/d) promotes formation of CaOx stones.
Phosphorus	855	mg/d	400-1300	Phosphorus forms insoluble complexes with calcium.
Sodium	148	mmol/d	51-286	Increased sodium promotes formation of CaOx and CaHPO4 stones.
Sulfate	20	mmol/d	6-30	Normal to high sulfate promotes precipitation of CaOx and CaHPO4 stones.
Uric Acid	488	mg/d	250-750	Hyperuricosuria (>600 mg/d) promotes formation of uric acid stones.

### **Stone Formation Inhibitors**

Analyte	Result	Units	Reference Interval	Effect
Citric Acid	745	mg/d	320-1240	High citrate inhibits formation of CaOx and CaHPO4 stones.
Magnesium	81	mg/d	12-199	High magnesium inhibits formation of CaOx and CaHPO4 stones.





Patient: ARUP Accession: 23-294-101287

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director

Chart continues on following page(s) ARUP Enhanced Reporting | October 26, 2023 | page 1 of 2

Patient: Patient Ider	ntifiers:	Date of Birth:   So   Visit Number (FIN):		Sex:	Physician:
Other Com	oonents				
Analyte	Result	Units	Reference Inte	rval	Effect
Potassium	54	mmol/d	25-125		Potassium forms soluble complexes.
Chloride	146	mmol/d	140-250		Chloride forms soluble complexes.

<sup>1</sup>Average calcium diet (about 800 mg/d).

Access complete set of age- and/or gender-specific reference intervals for this test in the ARUP Laboratory Test Directory (aruplab.com).

# Patient Historical Result Summary

No historical data found

## **Interpretive Information**

This test predicts formation of calcium oxalate, calcium hydrogen phosphate (brushite), and uric acid calculi using concentrations of analytes measured in a 24-hour urine specimen. Analyte concentrations are used in a calculation to predict formation of complexes that may exceed their solubility and crystallize as renal calculi. Development of renal calculi is related to increased urine concentrations of stone-forming substances such as calcium, oxalate, urate, cystine, and xanthine. Low urine volume enhances calculus formation. High concentrations of citrate and magnesium in the urine decrease the probability of stone formation.

This profile does not include testing for magnesium ammonium phosphate (struvite) or cystine calculi. If struvite stones associated with bacterial urinary tract infection are suspected, urinalysis and urine culture are recommended. If cystine calculi are suspected (calculi formation in relatively young individuals or family history of cystinuria), order Cystine Quantitative, Urine (ARUP test #0081106).

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

## **Software Reference**

Marangella M, Petrarulo M, Daniele PG, Sammartano S. LithoRisk: a software for calculating and visualizing nephrolithiasis risk profiles. G Ital Nefrol 2002; 19(6):693-8.



ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 23-294-101287